Brenner is AlloCure's new CEO
AlloCure Inc., a Burlington biotechnology company focused on using cell therapy for the treatment of kidney disease, announced the appointment of Robert M. Brenner, MD, (right) as its president and chief executive officer.
Brenner was previously senior vice president of Medical Affairs at AMAG Pharmaceuticals
"John Wirthlin, AlloCure's prior CEO, assumes the position of chief operating officer and remains a member of the company's management team," AlloCure said in a press release.
The photo of Brenner with this post was provided by the company.